Covaxin has been administered to roughly 25 million people till date in India and elsewhere. (File)
Washington:
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
India s Covaxin Effectively Neutralises Delta Variant, Says US National Institute Of Health
Results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise both Alpha and Delta variants of coronavirus.
Outlook Web Desk 30 June 2021, Last Updated at 11:38 am Representational Image Outlook Web Desk 2021-06-30T07:26:01+05:30 India s Covaxin Effectively Neutralises Delta Variant, Says US National Institute Of Health outlookindia.com 2021-06-30T11:38:13+05:30
The US National Institute of Health has said India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus.
WASHINGTON: India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
Search
Home / World / Covaxin effective against both Alpha and Delta variants of Covid, says US research institute Covaxin effective against both Alpha and Delta variants of Covid, says US research institute The vaccine comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, r
India s Covaxin effectively neutralises Delta variant of Covid, says NIH
PTI
Washington |
Updated on
The adjuvant used Alhydroxiquim-II is the first authorised against infectious disease. India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said. The NIH said results of two blood serum studies from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively. The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and